Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003

por Dudek, Arkadiusz Z., Liu, Li C., Gupta, Shilpa, Logan, Theodore F., Singer, Eric A., Joshi, Monika, Zakharia, Yousef N., Lang, Joshua M., Schwarz, James K., Al-Janadi, Anas, Alva, Ajjai S.
Publicado 2020

Cholesterol crystals induce mechanical trauma, inflammation, and neo-vascularization in solid cancers as in atherosclerosis

por Abela, George S., Katkoori, Venkat R., Pathak, Dorothy R., Bumpers, Harvey L., Leja, Monika, Abideen, Zain ul, Boumegouas, Manel, Perry, Daniel, Al-Janadi, Anas, Richard, James E., Barnaba, Carlo, Meza, Ilce G. Medina
Publicado 2023

Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy‐Naive Metastatic Castrate‐Resistant Prostate Cancer

por Heath, Elisabeth, Heilbrun, Lance, Mannuel, Heather, Liu, Glenn, Lara, Primo, Monk, J. Paul, Flaig, Thomas, Zurita, Amado, Mack, Philip, Vaishampayan, Ulka, Stella, Philip, Smith, Daryn, Bolton, Susan, Hussain, Arif, Al‐Janadi, Anas, Silbiger, Daniel, Usman, Muhammad, Ivy, S. Percy
Publicado 2019

Small Molecule 20S Proteasome Enhancer Regulates MYC Protein Stability and Exhibits Antitumor Activity in Multiple Myeloma

por Njomen, Evert, Vanecek, Allison, Lansdell, Theresa A., Yang, Ya-Ting, Schall, Peter Z., Harris, Christi M., Bernard, Matthew P., Isaac, Daniel, Alkharabsheh, Omar, Al-Janadi, Anas, Giletto, Matthew B., Ellsworth, Edmund, Taylor, Catherine, Tang, Terence, Lau, Sarah, Bailie, Marc, Bernard, Jamie J., Yuzbasiyan-Gurkan, Vilma, Tepe, Jetze J.
Publicado 2022